AccuLine was founded with the vision to save the lives of millions of people worldwide by preventing the next heart attack. AccuLine is developing CORA, an accurate, noninvasive, swift, and cost-effective examination for early detection of CAD, designed to replace the inaccurate, time-consuming, and labor-intensive stress test examinations.

Through a brief 4-minute evaluation of three vital signs – the heart’s electrical activity, oxygen saturation levels, and respiratory phase – CORA automatically generates results, ensuring a seamless and efficient process. CORA has the potential to save the lives of millions of patients worldwide while simultaneously decreasing healthcare-related costs.

Our TAMID analysts explored market research for CORA’s United States product rollout for potential challenges and ideal clinical users. The team also conducted survey outreach to local clinics and hospitals.